<?xml version='1.0' encoding='utf-8'?>
<document id="31095880"><sentence text="No Effect of Digoxin on Rosuvastatin Pharmacokinetics in Healthy Subjects: Utility of Oita Combination for Clinical Drug-Drug Interaction Study."><entity charOffset="13-20" id="DDI-PubMed.31095880.s1.e0" text="Digoxin" /><entity charOffset="24-36" id="DDI-PubMed.31095880.s1.e1" text="Rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.31095880.s1.e0" e2="DDI-PubMed.31095880.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31095880.s1.e0" e2="DDI-PubMed.31095880.s1.e1" /></sentence><sentence text="This study evaluated the utility of combination of digoxin (0"><entity charOffset="51-58" id="DDI-PubMed.31095880.s2.e0" text="digoxin" /></sentence><sentence text="25 mg) and rosuvastatin (5 mg) as a new transporter (P-glycoprotein/breast cancer resistance protein/organic anion-transporting polypeptide (OATP)1B1/OATP1B3) probe cocktail (Oita combination) for drug-drug interaction (DDI) studies by demonstrating lack of DDI of digoxin on the pharmacokinetics (PKs) of rosuvastatin, as it was already known that rosuvastatin did not affect digoxin PK"><entity charOffset="11-23" id="DDI-PubMed.31095880.s3.e0" text="rosuvastatin" /><entity charOffset="265-272" id="DDI-PubMed.31095880.s3.e1" text="digoxin" /><entity charOffset="306-318" id="DDI-PubMed.31095880.s3.e2" text="rosuvastatin" /><entity charOffset="349-361" id="DDI-PubMed.31095880.s3.e3" text="rosuvastatin" /><entity charOffset="377-384" id="DDI-PubMed.31095880.s3.e4" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.31095880.s3.e0" e2="DDI-PubMed.31095880.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31095880.s3.e0" e2="DDI-PubMed.31095880.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31095880.s3.e0" e2="DDI-PubMed.31095880.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31095880.s3.e0" e2="DDI-PubMed.31095880.s3.e3" /><pair ddi="false" e1="DDI-PubMed.31095880.s3.e0" e2="DDI-PubMed.31095880.s3.e4" /><pair ddi="false" e1="DDI-PubMed.31095880.s3.e1" e2="DDI-PubMed.31095880.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31095880.s3.e1" e2="DDI-PubMed.31095880.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31095880.s3.e1" e2="DDI-PubMed.31095880.s3.e3" /><pair ddi="false" e1="DDI-PubMed.31095880.s3.e1" e2="DDI-PubMed.31095880.s3.e4" /><pair ddi="false" e1="DDI-PubMed.31095880.s3.e2" e2="DDI-PubMed.31095880.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31095880.s3.e2" e2="DDI-PubMed.31095880.s3.e3" /><pair ddi="false" e1="DDI-PubMed.31095880.s3.e2" e2="DDI-PubMed.31095880.s3.e4" /><pair ddi="false" e1="DDI-PubMed.31095880.s3.e3" e2="DDI-PubMed.31095880.s3.e3" /><pair ddi="false" e1="DDI-PubMed.31095880.s3.e3" e2="DDI-PubMed.31095880.s3.e4" /></sentence><sentence text=" This was an open-label, two-period study in which the primary end points were the geometric mean ratio (GMR) of the area under the plasma rosuvastatin concentration-time curve from time zero to last (AUClast ) after rosuvastatin administration combined with digoxin to that after rosuvastatin administration alone and its 90% confidence interval (CI)"><entity charOffset="139-151" id="DDI-PubMed.31095880.s4.e0" text="rosuvastatin" /><entity charOffset="217-229" id="DDI-PubMed.31095880.s4.e1" text="rosuvastatin" /><entity charOffset="259-266" id="DDI-PubMed.31095880.s4.e2" text="digoxin" /><entity charOffset="281-293" id="DDI-PubMed.31095880.s4.e3" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.31095880.s4.e0" e2="DDI-PubMed.31095880.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31095880.s4.e0" e2="DDI-PubMed.31095880.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31095880.s4.e0" e2="DDI-PubMed.31095880.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31095880.s4.e0" e2="DDI-PubMed.31095880.s4.e3" /><pair ddi="false" e1="DDI-PubMed.31095880.s4.e1" e2="DDI-PubMed.31095880.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31095880.s4.e1" e2="DDI-PubMed.31095880.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31095880.s4.e1" e2="DDI-PubMed.31095880.s4.e3" /><pair ddi="false" e1="DDI-PubMed.31095880.s4.e2" e2="DDI-PubMed.31095880.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31095880.s4.e2" e2="DDI-PubMed.31095880.s4.e3" /></sentence><sentence text=" As the GMR of AUClast was 0" /><sentence text="974 and its 90% CI was 0" /><sentence text="911-1" /><sentence text="042, it was judged that digoxin does not affect rosuvastatin PK"><entity charOffset="24-31" id="DDI-PubMed.31095880.s8.e0" text="digoxin" /><entity charOffset="48-60" id="DDI-PubMed.31095880.s8.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.31095880.s8.e0" e2="DDI-PubMed.31095880.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31095880.s8.e0" e2="DDI-PubMed.31095880.s8.e1" /></sentence><sentence text=" Results of this study have rationalized utility of the Oita combination as a transporter probe cocktail for clinical DDI studies" /><sentence text="" /></document>